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ABSTRACT Very old (aged ⩾80 years) adults constitute an increasing proportion of the global
population. Currently, this subgroup of patients represents an important percentage of patients admitted
to the intensive care unit. Community-acquired pneumonia (CAP) frequently affects very old adults.
However, there are no specific recommendations for the management of critically ill very old CAP
patients. Multiple morbidities, polypharmacy, immunosenescence and frailty contribute to an increased
risk of pneumonia in this population. CAP in critically ill very old patients is associated with higher short-
and long-term mortality; however, because of its uncommon presentation, diagnosis can be very difficult.
Management of critically ill very old CAP patients should be guided by their baseline characteristics,
clinical presentation and risk factors for multidrug-resistant pathogens. Hospitalisation in intermediate
care may be a good option for critical ill very old CAP patients who do not require invasive procedures
and for whom intensive care is questionable in terms of benefit.
What is the role of community-acquired pneumonia in critically ill very old
patients?
Community-acquired pneumonia (CAP) is a major public health problem with high morbidity, mortality
and short- and long-term sequelae [1–4]. Very old (aged ⩾80 years) patients are at increased risk of
complications and death by most causes [5]. The incidence of CAP in very old patients continues to rise
[6]. The immunosenescence [7], multicomorbidities [8] and frailty [9] of these patients increases their
susceptibility to infectious diseases [10, 11]. Moreover, it is reported that CAP is associated with a 16%
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reduction in quality of life during the post-discharge year among elderly patients (mean age 76 years in
cases and controls) who survive to hospitalisation for CAP, compared to non-diseased persons [12].
Currently, due to their increased life expectation, over the past two decades the proportion of very old
patients admitted to intensive care units (ICUs) has grown significantly worldwide [6, 13, 14], increasing
healthcare costs [15–17]. The percentage of very old patients admitted to ICUs ranges from 9–20% in
several countries [13, 18–24]. A recent French study reported the 10-year (2006 to 2015) trends in ICU
admissions for respiratory infections in the elderly population. The authors found that the absolute
number and the percentage of elderly patients admitted to ICUs increased, with the greatest rise in
patients aged ⩾85 years (11% in 2006 versus 16% in 2015) [6]. Moreover, a recent Spanish study [25]
investigated risk factors for mortality in critically ill elderly and very old patients with sepsis in 77 ICUs.
Pneumonia was the main cause of sepsis, affecting 62% of very old patients; mortality for sepsis in very
old patients was 54%. Similarly, the study by CILLONIZ et al. [26] on the topic of sepsis secondary to CAP
in very old patients reported that 11% of these patients required ICU admission and 14% developed sepsis
with an ICU mortality of 17%.
In this review, we discuss important findings and gaps in knowledge concerning the management of
critically ill very old patients with CAP, and propose a series of recommendations to guide basic principles
of CAP management in these patients while further evidence is gathered (figure 1).
Clinical presentation of pneumonia in very old patients
Immunosenescence reduces the ability of very old patients to respond to an infection [27]. Some specific
symptoms of lower respiratory infection such as cough, fever and chest pain may be atypical in very old
patients with pneumonia [28], thus increasing the risk of misdiagnosis and delaying the initiation of the
empiric antimicrobial therapy [29, 30]. For these reasons, pneumonia may be associated with high
morbidity and mortality and poor long-term outcomes in this subgroup of patients [29, 31]. Falls, altered
mental status (e.g. delirium), fatigue, lethargy, anorexia, tachypnoea and tachycardia are the most frequent
symptoms associated with pneumonia in very old patients [32, 33]. Pneumonia may also be associated
with an exacerbation or decompensation of previous chronic comorbidities (diabetes mellitus, cardiac
disease, chronic pulmonary disease). Radiographic findings are inconclusive or difficult to interpret in
approximately 30% of cases [34]. The inadequate inflammatory response to an infection due to
immunosenescence [35, 36] may also lead to an underestimation of pneumonia severity. However, data
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FIGURE 1 General recommendations for the management of critically ill very old community-acquired
pneumonia (CAP) patients. PSI: pneumonia severity index; ATS: American Thoracic Society; ICU: intensive care
unit. #: in addition to the antibiotics recommended in guidelines, ceftaroline+macrolide/ceftobiprole
+macrolide could be a good option for this population.
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regarding the role of biomarkers (leukocyte count, C-reactive protein, procalcitonin) in the early diagnosis
and prognosis of pneumonia in critically ill very old patients are limited [37].
What parameters might help guide the management of CAP in critically ill very old
patients?
Since the short- and long-term prognosis of critically ill very old patients with CAP mostly depends on
previous functional status rather than on the severity of pneumonia at ICU admission, improved tools for
patient prognosis in this particular subgroup would be extremely helpful [31, 38].
Age-related changes: immunosenescence and sarcopenia
It is expected that in 2080, the current proportion of people aged ⩾80 years will have more than doubled,
from 6% to 13% of the European population [39].
Immunological age-related changes (immunosenescence) gradually reduce the efficiency of the innate and
adaptive immune systems [7]. Few naïve cells, increased dysfunctional memory cells and primary
lymphoid organ involution may explain the susceptibility of very old patients to infectious diseases,
especially those caused by Streptococcus pneumoniae and respiratory viruses [35]. Important barriers to
infection, such as the cough reflex and fever, are also affected by immunosenescence. Figure 2 shows
age-related changes in the innate and adaptive immune systems.
Sarcopenia is a geriatric syndrome characterised by a loss of skeletal muscle mass and a decrease of muscle
strength or physical performance. Some studies have reported that sarcopenia is an independent risk factor
for CAP and for some adverse outcomes (length of hospital stay, readmission or death) [40–43]. MARTINEZ
et al. [41] studied the frequency of sarcopenia in 110 hospitalised elderly patients. The prevalence of
sarcopenia in very old patients was 12%. Recently, a study from Peru [43] determined the incidence and
risk factors of CAP in older adults with sarcopenia. CAP affected 15% of sarcopenic patients, with a mean
age of 82 years. The authors reported that sarcopenia and smoking habits were risk factors for CAP.
Unfortunately, data regarding the prevalence and impact of sarcopenia in critically ill very old patients
with CAP are limited.
Comorbidities
Very old patients suffer from a variety of chronic diseases that affect the integrity of resistance to an
infection. Chronic respiratory diseases, diabetes mellitus, chronic heart disease, COPD and chronic
neurological diseases are the most frequent comorbidities reported in critically ill very old patients with
CAP [6, 11, 44]. They are associated with longer hospital stays, ICU admission, sepsis [45–47], hospital
readmission [48, 49] and mortality [11]. In a Spanish study assessing the impact of age and comorbidities
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FIGURE 2 Changes in the adaptive and innate immune system. INF: interferon; IL: interleukin; TNF: tumour
necrosis factor; Ig: immunoglobulin.
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on the aetiology of pneumonia, 80% of CAP patients had at least one comorbidity (chronic respiratory
disease, diabetes mellitus, chronic cardiovascular disease, neurological disease, chronic liver disease or
chronic renal disease) with rates varying according to age group, being 81% in patients aged >75 years.
The most frequent comorbidity in all the age groups was chronic pulmonary disease (54%). COPD was
the most frequent respiratory comorbidity, decreasing in frequency with age. The percentage of
comorbidities in critically ill very old patients and very old patients hospitalised on a general ward was
similar (81% versus 78%, p=0.26). However, diabetes mellitus was more frequent in critically ill very old
patients compared to very old patients hospitalised on general wards (22% versus 31%, p=0.012), whereas
neurological diseases were less frequent in critically ill very old patients than in very old patients
hospitalised on general wards (30% versus 17%, p=0.001) (data not published) [44].
Similarly, LUNA et al. [11] investigated the effect of age and comorbidities on CAP mortality in 6205
patients, reporting mortality rates of 14% in very old patients. Moreover, in patients with no or only one
comorbidity, age ⩾80 years was associated with increased mortality.
Recently, chronic renal disease and diabetes mellitus have been described as independent risk factors for
sepsis secondary to CAP in very old patients, while antibiotic therapy before admission was independently
associated with a lower risk of sepsis [26]. Chronic renal disease and neurological disease were reported as
independent risk factors for 30-day mortality in very old patients with sepsis secondary to CAP.
Malnutrition
Malnutrition is strongly related to the ageing of the immune system. In 2008, RIQUELME et al. [32] studied
the clinical and nutritional features of 109 elderly patients with CAP. They reported that 77% of patients
presented with malnutrition. In their multivariate analysis, malnutrition (OR 2.7), an albumin level
⩽3.4 g·dL−1 (OR 2.7) and brachial muscle perimeter ⩽24 cm (OR 4.0) were related to an increased risk of
in-hospital mortality.
Two recent papers confirmed the important role of malnutrition in the outcomes of CAP patients. The first
study evaluated risk factors associated with hospitalisation in 199 home-healthcare patients with CAP from
Taiwan; the mean age of the study population was 82±11 years [50]. The authors reported that 83% of
patients presented with anaemia and 34% with hypoalbuminaemia. In their multivariate analysis, anaemia
(OR 2.37) and hypoalbuminaemia (OR 1.57) significantly increased the risk of hospitalisation for CAP. The
second study evaluated the prevalence and prognostic value of malnutrition in two groups of CAP patients
(aged ⩾65 and <65 years) from Korea [51]. The authors found that the prevalence of malnutrition in the
entire cohort was 39%, and it was higher in the elderly group (53% versus 12%, p=0.001). Malnutrition (OR
2.52) and Charlson comorbidity index score (OR 1.30) were associated with 2-year mortality.
There are no data about malnutrition and critically ill very old patients with CAP. Since malnutrition is
associated with worse short- and long-term outcomes in very old patients with CAP, continual assessment
of patient nutritional status is recommended in order not to underestimate, underdiagnose or undertreat it.
Frailty
Frailty is associated with adverse clinical outcomes in older hospitalised patients. It is characterised by a
loss of biological reserves, a failure of homeostatic mechanisms and an increased vulnerability to
adversities such as falls, disability, hospitalisation, cognitive decline and loss of independence. The
prevalence of frailty rises steadily with age: from 4% in the 65–69-year-old group to 7% at 70–74 years, 9%
at 75–79 years, 16% at 80–84 years and 26% in the those aged ⩾85 years [52, 53]. A transnational
prospective study set up by the European Society of Intensive Care Medicine, with the participation of 311
ICUs from 21 European countries, investigated the impact of frailty on the outcomes of 5021 critically ill
very old patients. Frailty (values ⩾5 in the Clinical Frailty Scale (CFS)) was present in 43% of patients and
was independently related to 30-day survival [54].
Frailty should be measured in routine clinical practice in order to improve the management of elderly
patients with CAP. However, there is no international standard for its assessment. The CFS derived from
the Frailty Index (FI) proposed by ROCKWOOD et al. [55] is the most frequently used: FI=number of deficits
in an individual/total number of deficits measured. It includes variables that represent a range of states,
conditions and physiological systems such as mobility, disability, self-rated general health, eyesight, hearing
and chronic diseases. The CFS established nine categories for older people: 1) very fit; 2) well,
3) managing well; 4) vulnerable; 5) mildly frail; 6) moderately frail; 7) severely frail; 8) very severely frail;
and 9) terminally ill (figure 3).
In 2018, GILBERT et al. [56] proposed the Hospital Frailty Risk Score, which is based on 109 diagnostic field
codes from the National Health Service Hospital Episode Statistics database. The score was developed and
validated in three UK populations, with high prognostic performance. The score is divided into three
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categories: low frailty risk (score <5); intermediate frailty risk (5–15); and high frailty risk (>15). The score
was further validated in a tertiary care hospital in Switzerland [57]. The study population comprised 4957
patients: 64% were classified as low frailty risk, 34% as intermediate and 3% as high frailty risk. Patients at
intermediate and high frailty risk showed an increased risk of 30-day mortality (OR 2.53 and OR 4.40,
respectively, p<0.001) compared with patients in the low frailty risk group. The authors also found that
patients with higher frailty risk have longer hospital stay, more severe functional impairment and a lower
quality of life. The study confirmed the prognostic value of the Hospital Frailty Risk Score.
Polypharmacy
Because of their chronic conditions, older patients are at increased risk of polypharmacy [58], side-effects
and drug–drug interactions [59, 60].
In a study from Canada [61], including 2105 older CAP patients, 45% of patients used four or five
medications at baseline. Cardiovascular (63%), alimentary tract and metabolism (49%), nervous system
(47%), respiratory (38%), blood and blood-forming and general anti-infective for systemic use (21%) drugs
were the most frequently used. The authors also observed that in the 90-day period following a CAP
episode, the rate of patients with polypharmacy increased from 45% to 74%.
Because of their multiple comorbidities and polypharmacy, choosing empiric antimicrobial therapy may be
challenging in very old patients with infections such as pneumonia [60].
ICU benefit in very old patients: role of severity scores
Currently, 10–20% of all ICU admissions involve very old patients [18, 20–23, 44]. However, the
effectiveness of ICU management in this subgroup of patients remains controversial. Since not all very old
patients are fragile, advanced age per se should not be a limitation to receive critical care therapy.
1 Very Fit-People who are robust, active
energetic and motivated. These people
commonly exercise regularly. They are
among the fittest for their age.
2 Well-People who have no active disease
symptoms but are less fit than category 1.
Often, they exercise or are very active
occasionally, e.g. seasonally.
3 Managing Well-People whose medical
problems are well controlled, but are not
regularly active beyond routine walking.
4 Vulnerable-While not dependent on
others for daily help, often symptoms limit
activities. A common complaint is being
“slowed up”, and/or being tired during the day.
5 Mildly Frail-These people often have
more evident slowing, and need help in high
order IADLs (finances, transportation, heavy
housework, medications). Typically, mild
frailty progressively impairs shopping and
walking outside alone, meal preparation and
housework.
6 Moderately Frail-People need help with
all outside activities and with keeping house.
Inside, they often have problems with stairs
and need help with bathing and might need
minimal assistance (cuing, standby) with
dressing.
7 Severely Frail-Completely dependent
for personal care, from whatever cause
(physical or cognitive). Even so, they
seem stable and not at high risk of
dying (within 6 months).
8 Very Severely Frail-Completely
dependent, approaching the end of life.
Typically, they could not recover even
from a minor illness.
9 Terminally Ill-Approaching the end
of life. This category applies to people
with a life expectancy <6 months, who
are not otherwise evidently frail.
Scoring frailty in people with dementia
The degree of frailty corresponds to the degree of
dementia. Common symptoms in mild dementia
include forgetting the details of a recent event,
though still remembering the event itself, repeating
the same question/story and social withdrawal.
In moderate dementia, recent memory is very
impaired, even though they seemingly can remember
their past life events well. They can do personal care
with prompting.
In severe dementia, they cannot do personal care
without help.
FIGURE 3 Clinical Frailty Scale. IADLs: instrumental activities of daily living.
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Disease severity in CAP is used to assess the prognosis and to guide patient management [4]. In critically
ill very old patients with pneumonia, the lack of validated criteria and severity scores that accurately
identify those patients that would benefit from ICU admission represents a major issue [62]. The most
frequently used severity scores in CAP (pneumonia severity index (PSI) [63], CURB65 (confusion, (urea
>7 mmol·L−1), respiratory rate ⩾30 breaths·min−1, blood pressure < 90mmHg (systolic) ⩽60 mmHg
(diastolic), age ⩾65 years) and CRB65 [64]) have some limitations for elderly patients: in the PSI, age and
comorbidities score more highly, whereas in CRB65 and CURB65, the low number of variables affects the
inclusion of all patients with severe CAP.
The Eldicus study [65] investigated the effect of ICU triage decisions on mortality. Refusal benefited
overall mortality according to increasing age, where the group of patients aged >84 years had the highest
rate of mortality (36%).
More recently, in a Norwegian multicentre observational study [66], 30% of very old patients were refused
ICU treatment. Factors increasing the likelihood of ICU refusal in patients considered too ill/old were
advanced age, male sex, university hospital admission, comorbidity and low functional status.
Recently, a US study on pneumonia hospitalisation in adults [67] including 119537 patients, found that
approximately 19% required ICU admission and 13% required mechanical ventilation. The rate of
pneumonia hospitalisation with ICU admission was 76 per 100000 persons per year in the overall
population. In adults aged ⩾85 years, the rates of hospitalisation and ICU admission were 53 times higher
(4368 per 100000) and 46 times higher (695 per 100000) than in the younger group (18–49 years; 83 per
100000 persons per year for hospitalisation and 15 per 100000 persons per year for ICU admission).
A European study [6] of ICU admission due to respiratory infections in the elderly population (<75, 75–79,
80–84, 85–89 and ⩾90 years) over 10 years (2006 to 2015) was also published. The authors reported that
3% of all hospitalisations (n=3856785 cases) were due to an acute respiratory infection (n=98381 cases)
and that 15% of those cases required ICU admission (n=15267 cases). The authors found that there was an
overall increase in the number of ICU admissions for all age groups, but with the greatest increases in
patients aged 85–89 years (3.3-fold) and ⩾90 years (5.8-fold). Interestingly, the authors also reported that
the higher rate of ICU admission was not associated with significant changes in ICU mortality for patients
with an acute respiratory infection; rates were 19.7%±3.0%, 24.0%±3.6% and 25.0%±4.0% for the 75–79,
80–84 and 85–89 age groups, respectively. Indeed, the authors reported a significant drop in ICU mortality
from 41% in 2006 to 22% in 2015 (p=0.03) for patients aged ⩾90 years. Hospitalisations for CAP and
acute exacerbations of COPD increased significantly for all age groups over the 10-year study period.
Meanwhile, a multicentre, prospective study from Canada [68] including 1671 critically ill very old
patients who were admitted to 22 ICUs, reported that ICU mortality was 22%, with a median time from
ICU admission to death of 10 days. 49% of patients who died were still receiving mechanical ventilation,
vasopressors or dialysis.
A retrospective cohort analysis including 328404 elderly (>64 years) patients with pneumonia admitted to
ICUs in the USA [69] found potential benefit provided by ICU admission for older patients with low-risk
pneumonia. Compared to patients admitted to a general hospital ward, patients admitted to an ICU had
significantly lower adjusted 30-day mortality (15% versus 21, p=0.02) with no significant differences in
health costs associated with ICU admission.
A study by CHEN et al. [70] evaluated the performance of two scores (PSI and CURB65) in three groups of
CAP patients according to age: 18–64 years, 65–84 years and ⩾85 years. The authors found the worst
scores, mainly the PSI, in the group of patients aged 65–84 years and ⩾85 years. This may be due to an
overestimated weight of age. The authors therefore proposed a modified score excluding age for this
specific population.
Recently, SANZ et al. [71] proposed a composite score to predict mortality by combining PSI score and
Barthel index. In a study that included 1919 patients aged ⩾65 years, 61% had severe pneumonia (PSI IV–
V) and 40% had Barthel index ⩽90. The combination of PSI IV–V and Barthel index ⩽90 constituted the
greatest risk factor for mortality (OR 4.17).
Among the scores that predict ICU admission, the need for vasoactive drugs, or the need for mechanical
ventilation, the most commonly used are the SMART-COP tool [72], and the American Thoracic Society
(ATS)/Infectious Disease Society of America (IDSA) severity criteria score [73]. Age or comorbidities are
not included in the ATS/IDSA criteria since patient selection is based on acute physiologic parameters. In
the SMART-COP, the cut-off for age is 50 years.
Recently, DE LANGE et al. [74] proposed a Cumulative Prognostic Score (CPS) to predict 30-day mortality
in very old patients admitted to an ICU. Overall, 306 ICUs from 24 European countries participated in the
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study; 3730 very old patients with a median age of 84 years were included. The 30-day mortality rate was
42% (1562 deaths), with age, sex, ICU admission diagnosis, CFS, Sequential Organ Failure Assessment,
invasive mechanical ventilation and renal replacement therapy being predictors for mortality. The area
under the curve for a CPS of ⩾10 points was 0.80. The model predicted 30-day mortality in 91% of all
patients who died at a cut-off point of ⩾10 (75% of all patients). Although CPS seems to be a useful tool
to guide physicians, several factors relevant to very old patient populations (e.g. nutritional status,
functional status, dementia and comorbidities) have not been incorporated into the score.
In conclusion, clinical evaluation is the cornerstone when considering ICU admission of very old patients.
Age should not be the only factor guiding ICU admission. Delayed ICU admission is associated with a
higher risk of death. Patients who may benefit from ICU admission are those who have failed to benefit from
therapy during general hospitalisation, and patients requiring organ support or specific monitoring [75, 76].
What is the importance of intermediate care in critically ill very old patients?
In a study from 2014 including data from 167 ICUs in 17 European countries, CAPUZZO et al. [77]
evaluated whether adults admitted to hospitals with both ICUs and intermediate care units (IMCUs) had
lower in-hospital mortality than patients with no IMCU option. The study included 5834 patients: 1397
(24%) died in the hospital and 19% in the ICU. Overall, 5031 (86%) patients were admitted to hospitals
with IMCUs and 803 (14%) to those without IMCUs. After adjustments for patient characteristics (illness
severity, ICU) and hospital characteristics (number of hospital beds, ICU beds, teaching hospital, for-profit
hospital, possibility of extra beds in the ICU, patient ratio in daytime for ICU nurses), the authors
reported that the presence of an IMCU in the hospital significantly reduced mortality for adult patients
(OR 0.63 (95% CI 0.45–0.88); p=0.007) compared to centres without IMCUs.
Few prospective studies compared mortality in IMCUs and ICUs in very old patients with CAP. IMCUs
require less human and technical resources, thus potentially providing a practical alternative for critically
ill very old patients who do not require invasive procedures and whose ICU admission is questionable in
terms of benefit. IMCUs offer the option of stepping up to ICU care or stepping down to general
hospitalisation [78]. Notwithstanding this, evidence supporting the use of IMCUs in critically ill very old
patients is scanty and further studies are needed in order to provide specific recommendations for the use
of intermediate care in these patients.
Is microbial aetiology in very old patients different from that of the general
population?
Overall, CAP causative agents in the elderly differ from those of other age groups because of a higher rate
of pneumococcal and influenza infections as well as a lower rate of atypical microorganisms [79].
In 2003, the study by FERNANDEZ-SABE et al. [80] that investigated the aetiology and outcomes of CAP in
very old patients, reported that S. pneumoniae was the main pathogen that caused CAP in very old
patients. Legionella and atypical microorganism were very rarely found in very old patients with CAP.
In 2013, a study by our research group, investigated the effect of age and comorbidities on the microbial
aetiology of CAP [44]. Our results showed that microbiological diagnosis in CAP decreased with each
increasing age group (65–74 years: 43.7%; 75–84 years: 40.7%; and ⩾85 years: 31.4% (p<0.001)), and age
did not influence microbial aetiology by itself. S. pneumoniae was the pathogen most frequently reported
in all age groups (40.7%, 39.4% and 48.9%, respectively), followed by mixed aetiology (16.0%, 13.1% and
10.6%, respectively), atypical pathogens (16.0%, 13.1% and 9.9%, respectively) and respiratory viruses
(8.4%, 14.6% and 11.3%, respectively). In patients with at least one comorbidity Haemophilus influenzae
was the most common pathogen; multidrug-resistant (MDR) pathogens were frequent in patients with one
or more comorbidities. GROSS et al. [81] found that independent predictors of MDR pathogens in CAP
were similar to those identified for other infections (i.e. Pseudomonas aeruginosa) colonisation/infection in
the previous year, antimicrobial use in the previous 90 days, admission from a nursing home and duration
of hospitalisation in the previous 90 or 180 days.
In 2015, another Spanish study [82] proposed the acronym PES for a group of pathogens (P. aeruginosa,
Enterobacteriaceae extended-spectrum β-lactamase positive (ESBL+) and methicillin-resistant
Staphylococcus aureus (MRSA)) that cause CAP in approximately 6% of cases with a microbiological
diagnosis. The authors proposed the “PES score” to identify patients at higher risk of CAP caused by PES.
However, the PES score (table 1) lacks a specific age threshold for very old patients and this and other
scores need further validation before being systematically recommended in the assessment of MDR
microorganisms in CAP occurring in very old patients.
More recently, a study from China [83] evaluated the impact of adherence to current antimicrobial
guidelines on the mortality of 3131 hospitalised elderly CAP patients. The authors reported that the rate of
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patients admitted to ICUs increased by age group: 6% in the age group 65–74 years; 9% in the age group
75–84 years; and 14% in the age group >85 years. Microbial aetiology was defined in 14% of patients.
P. aeruginosa was the most common pathogen (20%), followed by Klebsiella pneumoniae (15%),
respiratory viruses (14%), Escherichia coli (10%), Acinetobacter spp., (8%), S. aureus (7%), S. pneumoniae
(3%) and atypical pathogens (0.6%).
FERRER et al. [84] analysed prognostic factors for severe CAP in 664 immunocompetent patients, 154 (23%)
of whom were ventilated and 510 (77%) who were non-ventilated; the mean age was 72 years in the
nonventilated group and 66 in the ventilated group. Microbial aetiology was established in 51% of patients.
S. pneumoniae was the main pathogen in both groups, polymicrobial aetiology was more frequent in
patients invasively ventilated and Legionella pneumophila was less frequent.
In a recent study about sepsis in very old patients with CAP, we observed that an aetiologic diagnosis was
achieved more often in very old patients with sepsis compared to very old patients without sepsis (34%
versus 27%; p=0.01) [26]. Although these data were not published, we found that the microbial aetiology
was similar in very old patients admitted to general wards and those admitted to ICU. S. pneumoniae was
the most frequent pathogen detected in both groups (43% versus 53%, p=0.094). Interestingly,
polymicrobial aetiology was the second most frequent aetiology in very old patients admitted to ICU (10%
versus 12%, p=0.44), whereas respiratory viruses were the second more frequent aetiology in very old
patients hospitalised in general wards (18% versus 9%, p=0.0043).
An international study [85] recently found that risk factors independently associated with CAP due to
Enterobacteriaceae were male sex, severe CAP, underweight (body mass index <18.5 kg·m−2) and previous
ESBL infection. In addition, previous ESBL infection, being underweight, cardiovascular diseases and
hospitalisation in the last 12 months were independently associated with MDR Enterobacteriaceae CAP.
In addition to MDR pathogens, microorganisms associated with aspiration pneumonia should be taken
into account when approaching microbiologic diagnosis of CAP in very old patients. Aspiration
pneumonia, frailty and dementia are tightly intertwined. Findings of pathogens potentially associated with
aspiration in CAP occurring in the elderly widely vary and are probably underestimated overall [86].
In brief, CAP in very old patients is caused by the same microorganisms than other age groups. However,
increasing age is a risk factor for Enterobacteriaceae and MDR pathogens. Other risk factors for MDR
CAP, such as residence in nursing homes, previous colonisation or use of antibiotics, as well as the risk of
aspiration pneumonia due to swallowing difficulties should be carefully assessed before instauration of
empirical treatment and for deciding preventive contact isolation at admission among other measures.
Risk scores, such as PES score, might be of utility but are not adapted to the very old patient population.
Principles for guiding empiric antimicrobial therapy of CAP in very old patients
Antibiotic therapy in critically ill very old patients should take into account age-related changes in the
tolerance, metabolism and excretion of antimicrobials, as well as drug–drug interactions [87].
Current international guidelines for the management of CAP patients [4, 88] do not provide a specific
recommendation for critically ill very old patients. Table 2 summarises the antibiotic therapy
recommended in patients with CAP requiring ICU admission.
TABLE 1 Pseudomonas aeruginosa, extended-spectrum β-lactamase-positive







Previous antibiotic use in the past month 2
Chronic respiratory disorder 2
Chronic renal failure 3
At emergency room
Consciousness impairment or aspiration evidence 2
Fever or shivers −1
⩽1 point: low-risk multidrug-resistant score; 2–4 points: medium-risk multidrug-resistant score; ⩾5
points: high-risk multidrug-resistant score.
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As stated, the risk of aspiration should be assessed to decide whether an anaerobicidal agent might be
included and risk factors for MRSA, P. aeruginosa and other Gram-negative bacilli should also be assessed
when selecting antibiotic treatment. Furthermore, apart from the recommendations included in current
guidelines, there are other options that might be advantageous for treating CAP in critically ill very old
patients. For instance, new generation cephalosporines might play an important role in this setting.
Ceftaroline is a fifth-generation cephalosporine. Compared to ceftriaxone, it provides better coverage
against S. pneumoniae and S. aureus (both MRSA and methicillin-sensitive Staphylococcus aureus) in
patients with CAP. Results from the Focus studies [89, 90] and the CAPTURE study [91] demonstrated its
efficacy in older patients with CAP caused by one of these microorganisms. Ceftobiprole is also a new
cephalosporin active against S. pneumoniae, S. aureus (MRSA and methicillin-sensitive Staphylococcus
aureus) and a substantial proportion of P. aeruginosa. It is indicated in CAP [92] and hospital-acquired
pneumonia but not ventilator-associated pneumonia. Ceftobiprole may be a reasonable option to cover
P. aeruginosa in addition to S. pneumoniae and S. aureus. None of these cephalosporines is effective
against ESBL Enterobacteriaceae.
There are other new antibiotics in the pipeline that due to their pharmacokinetic/pharmacodynamic
properties, spectrum or tolerability might end up being added to the armamentarium for treating CAP in
very old patients. AMALAKUHAN et al. [93] analysed solithromycin, pristinamycin, nemonoxacin, lefamulin,
omadacycline, ceftobiprole and delafloxacin by applying to them the San Antonio NIPS Model (N: novelty of
mechanism; I: avoidance of interactions and intolerance; P: favourable pharmacokinetic/pharmacodynamic
profile; S: simplicity of dosing). Nemonoxacin and delafloxacin both had a high NIPS index.
Corticosteroids as adjunctive therapy
A randomised study that investigated the effect of corticosteroids on treatment failure among patients with
severe CAP (according to ATS/IDSA criteria) with high inflammatory response (initial levels of
CRP>15 mg·dL−1) reported that treatment failure was less frequent in patients in the corticosteroid group
(13%) compared to patients in the placebo group (31%; p=0.02) and in-hospital mortality was similar
between groups (10% versus 15%; p=0.37) [94].
Several studies and meta-analyses have shown a reduction in the risk of progression to respiratory distress,
a shorter time to clinical stability and a shorter duration of hospital stay in patients with severe CAP
receiving adjunctive therapy with corticosteroids [95–97]. The latest ATS/IDSA guidelines do not routinely
recommend the use of corticosteroids in adults with severe CAP (conditional recommendation, moderate
quality of evidence). However, corticosteroids are suggested in CAP patients with refractory septic shock
[4]. Nonetheless, there is no specific evidence available on the use of adjunctive corticosteroids in very old
patients with CAP.
Sepsis as a complication in critically ill very old patients with CAP
A 2012 study assessing the impact on outcome of severe sepsis in which the most frequent site of infection
was the lung (46%) showed large differences in ICU mortality by age group (46%, 61% and 79% for
TABLE 2 Guidelines for the management and treatment for community-acquired pneumonia
Pneumonia
severity Moderate severity High severity
BTS
guidelines
1. CURB65 score 2 1. CURB65 score 3–5
Treat with oral/i.v. amoxicillin
+clarithromycin or doxycycline,
moxifloxacin or levofloxacin
Treat with co-amoxiclav plus clarithromycin/





1. Direct admission to intensive care unit: septic shock requiring vasopressor support
and/or respiratory failure requiring intubation and ventilation
β-lactam plus a macrolide or fluoroquinolone
BTS: British Thoracic Society; ATS: American Thoracic Society; IDSA: Infectious Disease Society of
America; CURB65: confusion, urea >7 mmol·L−1, respiratory rate ⩾30 breaths·min−1, blood pressure
<90mmHg (systolic) ⩽60 mmHg (diastolic), age ⩾65 years.
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<60 years, 60–80 years and very old patients, respectively). Moreover, age was the only variable
independently associated with ICU mortality in the multivariate analysis (OR 1.038) [98].
A recent prospective multicentre study including 1490 patients from 77 ICUs in Spain investigated
mortality risk factors in critically ill elderly (65–79 years) and very old patients with sepsis. The overall
hospital mortality was 49% (n=727) and was significantly higher in very old patients compared to elderly
patients (54% versus 47%; p=0.02). Predictors of hospital mortality in very old patients with sepsis were
age, APACHE II score and prompt adherence to the resuscitation bundles. In 2016, MONTULL et al. [46]
identified severe sepsis in 37% of 4070 CAP patients. The authors reported that severe sepsis CAP was
independently associated with older age, alcohol abuse, COPD and renal disease, whereas previous
antibiotic therapy was a protective factor. In another Spanish cohort study [26] that included 1238 very
old patients with CAP, 71% presented with sepsis according to the Sepsis-3 definition. Male sex, chronic
renal disease and diabetes mellitus were independent sepsis risk factors, while antibiotic therapy before
admission was independently associated with a lower risk of sepsis. The authors also reported that
in-hospital mortality was significantly higher in very old patients with sepsis than in nonseptic patients
(15% versus 9%, p=0.006).
More recently, CILLÓNIZ et al. [99] investigated pure viral sepsis in CAP patients and reported that
viral sepsis, defined according to the Sepsis-3 criteria, affected 19% of patients with a diagnosis of viral
pneumonia admitted to ICUs. Interestingly, male sex and age ⩾65years were risk factors for pure viral
sepsis; however, pure viral sepsis was not a risk factor for in-hospital mortality. In this study 9% of
patients were critically ill very old patients and viral sepsis was present in 11% (data not published).
Critically ill very old patients presenting with CAP and sepsis must be quickly identified: the atypical
presentation of pneumonia and sepsis in this subgroup of patients may alert physicians in order to reduce
the complications associated with a delay in the start of the empiric antimicrobial therapy.
What is the relationship between hospital discharge and readmission?
The rate of 30-day readmission in very old patients varies from 8–27% [48, 100–102]. Unfortunately, there
is limited information about readmission rates in critically ill very old patients with CAP. Readmission is
related to preventable and nonpreventable factors. Two studies reported data on preventable factors,
although were not specific for critically ill very old patients. In 2017, DONG et al. [100] investigated 2892
CAP patients, 15% of whom were readmitted; 40% were ⩾65 years and 33% of them were readmitted. In
this group of patients, the distribution of discharge was as follows: home without services (43%); home
with healthcare (26%); skilled nursing or subacute rehabilitation facility (16%); and acute rehabilitation or
long-term acute care facility (15%). 20% of patients discharged with healthcare and 12% of patients
discharged without home services were readmitted. Surprisingly, being discharged with healthcare was
associated with a markedly greater risk of readmission in the multivariate regression model (OR 1.58, 95%
CI 1.21–2.07). Interestingly, in 2015, FLAATTEN et al. [68] reported that among 1671 critically ill very old
patients, 20% were discharged to a long-term care facility, 46% went home and 3% went to a rehabilitation
facility. Unfortunately, the authors did not report the rate of readmission.
TOLEDO et al. [48] included 1756 patients with CAP, whose readmission rates were 28%, 49% and 23%, for
age groups 65–74 years, 75–84 years and >84 years, respectively. The overall rate of readmission among
ICU patients was 6%; however, percentages by age group were not reported. In the multivariate analysis of
factors related to readmission, the only preventable factor was discharge with home healthcare (OR 5.61,
95% CI 1.70–18.50). The authors suggested an inadequate evaluation of patient stability at the time of
hospital discharge as a possible explanation.
Overall, these data reflect the importance of discharge disposition as a factor related to readmission in
critically ill very old patients with CAP, as well as the need to systematically report these variables in
clinical studies.
Long-term outcomes in critically ill very old patients with CAP
During the past decade, several studies reported data about long-term consequences of CAP [103–111].
Major adverse cardiac events have been described during pneumonia hospitalisation and up to 10 years
after an episode of CAP, with a prevalence ranging between 10% and 30%, especially in case of
pneumococcal pneumonia, elderly patients and severe pneumonia [109, 112–117]. New-onset or
worsening heart failure, arrhythmias, stroke and acute coronary syndrome can be an expression of major
adverse cardiac events in CAP patients. In a non-human primate model of severe pneumococcal
pneumonia, REYES et al. [112] showed that Pneumococcus invaded the myocardium and induced cardiac
injury with necroptosis and apoptosis, followed by cardiac scarring after antibiotic therapy.
CORRALES-MEDINA et al. [114] investigated the risk of heart failure after hospitalisation for CAP in elderly
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patients (median age 77 years). The authors reported that the rate of new-onset heart failure increased
following hospital discharge: 30–90 days: 3%; 91 days to 6 months: 6%; 6 months to 1 year: 9%; 1–5 years:
20%; and >5 years from hospital discharge: 31%.
HEYLAND et al. [118] evaluated 12-month outcomes in critically ill very old patients after ICU discharge.
The study included 610 critically ill very old patients admitted to ICU for at least 24 h. ICU, hospital and
12 months after ICU admission mortality were 14%, 26% and 44%, respectively. 75% of critically ill very
old patients admitted to ICU survived and returned to their basic levels of physical function at 1 year.
The study by FERRANTE et al. [119] evaluated the relationship between frailty and post-ICU disability in
266 elderly and very old patients (mean age 84 years) admitted to ICU. The authors reported that frailty,
prefrailty and nonfrailty were present in 45%, 43% and 12% of patients, respectively. In the multivariable
analysis, frailty was associated with 41% greater disability over the 6 months following a critical illness
compared to nonfrailty, whereas prefrailty conferred a 28% greater risk of post-ICU disability compared to
nonfrailty. Mortality 6 months after ICU admission was twice as high among participants with frailty
(55%) compared to those who were prefrail (25%) or nonfrail (26%).
Advanced age is known to be associated with high-risk of long-term mortality. In 2011, ROCH et al. [20]
evaluated factors influencing short- and long-term outcomes in 299 critically ill very old patients following
ICU admission. The authors reported 46% of ICU mortality and 55% of hospital mortality. A higher SAPS
II score at ICU admission, the existence of a fatal disease (as reflected by the McCabe score), and a cardiac
diagnosis at admission were associated with hospital mortality. 1- and 2-year mortality rates were 72% and
79%, respectively.
A French study of 317 critically ill very old patients reported that 6-month and 1-year mortality after
discharge were 56% and 70%, respectively [17]. Another study from Germany, including 372 critically ill
very old patients [120], reported that in the overall population 3 months and 1 year after discharge survival
was 53% and 35%, respectively. In patients aged ⩾65 years with CAP, mortality at 6 months was reported
to be 19% and mortality at 1 year was 41% [107, 121]. In a study published by our research group [26] we
reported 22% of 1-year mortality in very old patients with sepsis secondary to CAP.
Vaccination and other prevention measures for CAP in very old patients
Current international guidelines recommend specific measures for preventing CAP [4, 73, 88, 122]. The
use of pneumococcal vaccines (polysaccharide and conjugate) and influenza vaccines are the most
important of these. Intervention in the lifestyle for modifiable risk factors for CAP will also help to reduce
the risk of pneumonia in very old patients [123]. Figure 4 summarises the main prevention measures for
CAP.
Pneumococal vaccines: two vaccines are currently available: the 13-valent pneumococcal







Influenza vaccine: annual vaccination is recommended.
Lifestyle interventions: stopping smoking, reducing alcohol consumption, having regular dental
checks and maintaining good nutritional status, try to minimise contact with children who have
acute viral respiratory infections.
PCV13 PPSV23
8 weeks
1 year (8 weeks) PCV13
At least 1 year apart for most
immunocompetent adults
FIGURE 4 Prevention of community-acquired pneumonia.
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Conclusion
The burden of CAP among critically ill very old patients is high, encompassing significant morbidity,
mortality and health costs worldwide. The presence of multiple comorbidities, polypharmacy and frailty
characterises these patients and increases the risk of infectious diseases, such as pneumonia. Early
recognition and diagnosis of CAP and its complications, such as sepsis, allows for the prompt initiation of
the antibiotic therapy. However, due to its atypical presentation in very old patients, the diagnosis of
pneumonia may be difficult in some cases. Preventive interventions are of pivotal importance to improve
outcomes and reduce the occurrence of adverse consequences.
Author contributions: C. Cillóniz, C. Dominedò, J.M. Pericàs, D. Rodriguez-Hurtado and A. Torres conceived this
review, provided their expertise for it, wrote the draft manuscript and contributed to its revision. All authors have read
and approved the final manuscript.
Conflict of interest: None declared.
Support statement: Publication was funded by Ciber de Enfermedades Respiratorias (CibeRes CB06/06/0028) and the
2009 Support to Research Groups in Catalonia 911, IDIBAPS (CERCA Programme/Generalitat de
Catalunya). C. Cillóniz is the recipient of a postdoctoral grant (Strategic Plan for Research and Innovation in
Health-PERIS 2016–2020), SEPAR fellowship 2008 and the Fondo de Investigación Sanitaria (grant PI19/00207).
Funding information for this article has been deposited with the Crossref Funder Registry.
References
1 Cillóniz C, Liapikou A, Martin-Loeches I, et al. Twenty-year trend in mortality among hospitalized patients with
pneumococcal community-acquired pneumonia. PLoS One 2018; 13: e0200504.
2 Arnold FW, Wiemken TL, Peyrani P, et al. Mortality differences among hospitalized patients with
community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia
Organization (CAPO) International Cohort Study. Respir Med 2013; 107: 1101–1111.
3 Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect
Dis 2013; 26: 151–158.
4 Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired
pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases
Society of America. Am J Respir Crit Care Med 2019; 200: e45–e67.
5 World Health Organization. Men Ageing and Health. Achieving Health Across the Life Span. Geneva, WHO,
1999.
6 Laporte L, Hermetet C, Jouan Y, et al. Ten-year trends in intensive care admissions for respiratory infections in
the elderly. Ann Intensive Care 2018; 8: 84.
7 Krone CL, van de Groep K, Trzciński K, et al. Immunosenescence and pneumococcal disease: an imbalance in
host-pathogen interactions. Lancet Respir Med 2014; 2: 141–153.
8 Weir DL, Majumdar SR, McAlister FA, et al. The impact of multimorbidity on short-term events in patients with
community-acquired pneumonia: prospective cohort study. Clin Microbiol Infect 2015; 21: 264.e7–264.e13.
9 Xue Q-L. The frailty syndrome: definition and natural history. Clin Geriatr Med 2011; 27: 1–15.
10 Cillóniz C, Rodríguez-Hurtado D, Torres A. Characteristics and management of community-acquired pneumonia
in the era of global aging. Med Sci (Basel) 2018; 6: E35.
11 Luna CM, Palma I, Niederman MS, et al. The impact of age and comorbidities on the mortality of patients of
different age groups admitted with community-acquired pneumonia. Ann Am Thorac Soc 2016; 13: 1519–1526.
12 Mangen M-JJ, Huijts SM, Bonten MJM, et al. The impact of community-acquired pneumonia on the
health-related quality-of-life in elderly. BMC Infect Dis 2017; 17: 208.
13 Nielsson MS, Christiansen CF, Johansen MB, et al. Mortality in elderly ICU patients: a cohort study. Acta
Anaesthesiol Scand 2014; 58: 19–26.
14 Fuchs L, Chronaki CE, Park S, et al. ICU admission characteristics and mortality rates among elderly and very
elderly patients. Intensive Care Med 2012; 38: 1654–1661.
15 Rozenbaum MH, Mangen M-JJ, Huijts SM, et al. Incidence, direct costs and duration of hospitalization of
patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis.
Vaccine 2015; 33: 3193–3199.
16 McLaughlin JM, Johnson MH, Kagan SA, et al. Clinical and economic burden of community-acquired
pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study. Infection 2015; 43:
671–680.
17 Le Borgne P, Maestraggi Q, Couraud S, et al. Critically ill elderly patients (⩾90 years): Clinical characteristics,
outcome and financial implications. PLoS One 2018; 13: e0198360.
18 Bagshaw SM, Webb SAR, Delaney A, et al. Very old patients admitted to intensive care in Australia and New
Zealand: a multi-centre cohort analysis. Crit Care 2009; 13: R45.
19 Reinikainen M, Uusaro A, Niskanen M, et al. Intensive care of the elderly in Finland. Acta Anaesthesiol Scand
2007; 51: 522–529.
20 Roch A, Wiramus S, Pauly V, et al. Long-term outcome in medical patients aged 80 or over following admission
to an intensive care unit. Crit Care 2011; 15: R36.
21 Tabah A, Philippart F, Timsit JF, et al. Quality of life in patients aged 80 or over after ICU discharge. Crit Care
2010; 14: R2.
22 Pavoni V, Gianesello L, Paparella L, et al. Outcome and quality of life of elderly critically ill patients: an Italian
prospective observational study. Arch Gerontol Geriatr 2012; 54: e193–e198.
23 Andersen FH, Kvåle R. Do elderly intensive care unit patients receive less intensive care treatment and have
higher mortality? Acta Anaesthesiol Scand 2012; 56: 1298–1305.
https://doi.org/10.1183/16000617.0126-2019 12
COMMUNITY-ACQUIRED PNEUMONIA | C. CILLÓNIZ ET AL.
24 Flaatten H, de Lange DW, Artigas A, et al. The status of intensive care medicine research and a future agenda for
very old patients in the ICU. Intensive Care Med 2017; 43: 1319–1328.
25 Martin-Loeches I, Guia MC, Vallecoccia MS, et al. Risk factors for mortality in elderly and very elderly critically
ill patients with sepsis: a prospective, observational, multicenter cohort study. Ann Intensive Care 2019; 9: 26.
26 Cilloniz C, Dominedò C, Ielpo A, et al. Risk and prognostic factors in very old patients with sepsis secondary to
community-acquired pneumonia. J Clin Med 2019; 8: E961.
27 Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009; 22:
1041–1050.
28 Gutiérrez F, Masiá M. Improving outcomes of elderly patients with community-acquired pneumonia. Drugs
Aging 2008; 25: 585–610.
29 Cilloniz C, Ceccato A, San Jose A, et al. Clinical management of community acquired pneumonia in the elderly
patient. Expert Rev Respir Med 2016; 10: 1211–1220.
30 Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in
community-acquired pneumonia. Chest 2006; 130: 11–15.
31 Zhang ZX, Yong Y, Tan WC, et al. Prognostic factors for mortality due to pneumonia among adults from
different age groups in Singapore and mortality predictions based on PSI and CURB-65. Singapore Med J 2018;
59: 190–198.
32 Riquelme R, Riquelme M, Rioseco ML, et al. [Community-acquired pneumonia in the elderly: clinical and
nutritional aspects]. Rev Med Chil 2008; 136: 587–593.
33 Saldías Peñafiel F, O’Brien Solar A, Gederlini Gollerino A, et al. [Community-acquired pneumonia requiring
hospitalization in immunocompetent elderly patients: clinical features, prognostic factors and treatment]. Arch
Bronconeumol 2003; 39: 333–340.
34 González Del Castillo J, Martín-Sánchez FJ, Llinares P, et al. [Consensus guidelines for the management of
community acquired pneumonia in the elderly patient]. Rev Esp Geriatr Gerontol 2014; 49: 279–291.
35 Murray MA, Chotirmall SH. The impact of immunosenescence on pulmonary disease. Mediators Inflamm 2015;
2015: 692546.
36 Solana R, Tarazona R, Gayoso I, et al. Innate immunosenescence: effect of aging on cells and receptors of the
innate immune system in humans. Semin Immunol 2012; 24: 331–341.
37 Nouvenne A, Ticinesi A, Folesani G, et al. The association of serum procalcitonin and high-sensitivity C-reactive
protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study.
BMC Geriatr 2016; 16: 16.
38 Azoulay E, Vincent J-L, Angus DC, et al. Recovery after critical illness: putting the puzzle together – a consensus
of 29. Crit Care 2017; 21: 296.
39 World Health Organization. Ageing and Health. www.who.int/news-room/fact-sheets/detail/ageing-and-health
Date last accessed: 12 March 2019. Date last updated: 05 May 2018.
40 Cruz-Jentoft AJ, Kiesswetter E, Drey M, et al. Nutrition, frailty, and sarcopenia. Aging Clin Exp Res 2017; 29: 43–48.
41 Martinez BP, Batista AKMS, Gomes IB, et al. Frequency of sarcopenia and associated factors among hospitalized
elderly patients. BMC Musculoskelet Disord 2015; 16: 108.
42 Tanimoto Y, Watanabe M, Sun W, et al. Association between sarcopenia and higher-level functional capacity in
daily living in community-dwelling elderly subjects in Japan. Arch Gerontol Geriatr 2012; 55: e9–e13.
43 Altuna-Venegas S, Aliaga-Vega R, Maguiña JL, et al. Risk of community-acquired pneumonia in older adults
with sarcopenia of a hospital from Callao, Peru 2010–2015. Arch Gerontol Geriatr 2019; 82: 100–105.
44 Cillóniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in
community-acquired pneumonia. Chest 2013; 144: 999–1007.
45 Kofteridis DP, Giourgouli G, Plataki MN, et al. Community-acquired pneumonia in elderly adults with type 2
diabetes mellitus. J Am Geriatr Soc 2016; 64: 649–651.
46 Montull B, Menéndez R, Torres A, et al. Predictors of severe sepsis among patients hospitalized for
community-acquired pneumonia. PLoS One 2016; 11: e0145929.
47 Nasa P, Juneja D, Singh O. Severe sepsis and septic shock in the elderly: an overview. World J Crit Care Med
2012; 1: 23–30.
48 Toledo D, Soldevila N, Torner N, et al. Factors associated with 30-day readmission after hospitalisation for
community-acquired pneumonia in older patients: a cross-sectional study in seven Spanish regions. BMJ Open
2018; 8: e020243.
49 Millett ERC, De Stavola BL, Quint JK, et al. Risk factors for hospital admission in the 28 days following a
community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation
rates over time: a cohort study. BMJ Open 2015; 5: e008737.
50 Lin C-J, Chang Y-C, Tsou M-T, et al. Factors associated with hospitalization for community-acquired
pneumonia in home health care patients in Taiwan. Aging Clin Exp Res 2020:32; 149–155.
51 Yeo HJ, Byun KS, Han J, et al. Prognostic significance of malnutrition for long-term mortality in
community-acquired pneumonia: a propensity score matched analysis. Korean J Intern Med 2019; 34: 841–849.
52 Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013; 381: 752–762.
53 Collard RM, Boter H, Schoevers RA, et al. Prevalence of frailty in community-dwelling older persons: a
systematic review. J Am Geriatr Soc 2012; 60: 1487–1492.
54 Flaatten H, De Lange DW, Morandi A, et al. The impact of frailty on ICU and 30-day mortality and the level of
care in very elderly patients (⩾80 years). Intensive Care Med 2017; 43: 1820–1828.
55 Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people.
CMAJ 2005; 173: 489–495.
56 Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing
on older people in acute care settings using electronic hospital records: an observational study. Lancet 2018; 391:
1775–1782.
57 Eckart A, Hauser SI, Haubitz S, et al. Validation of the hospital frailty risk score in a tertiary care hospital in
Switzerland: results of a prospective, observational study. BMJ Open 2019; 9: e026923.
58 Guidet B, Vallet H, Boddaert J, et al. Caring for the critically ill patients over 80: a narrative review. Ann
Intensive Care 2018; 8: 114.
https://doi.org/10.1183/16000617.0126-2019 13
COMMUNITY-ACQUIRED PNEUMONIA | C. CILLÓNIZ ET AL.
59 Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 2005;
40: 997–1004.
60 Corsonello A, Abbatecola AM, Fusco S, et al. The impact of drug interactions and polypharmacy on
antimicrobial therapy in the elderly. Clin Microbiol Infect 2015; 21: 20–26.
61 Gamble J-M, Hall JJ, Marrie TJ, et al. Medication transitions and polypharmacy in older adults following acute
care. Ther Clin Risk Manag 2014; 10: 189–196.
62 Hoffman KR, Loong B, Haren FV. Very old patients urgently referred to the intensive care unit: long-term
outcomes for admitted and declined patients. Crit Care Resusc 2016; 18: 157–164.
63 Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired
pneumonia. N Engl J Med 1997; 336: 243–250.
64 Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study.
Thorax 2000; 55: 219–223.
65 Sprung CL, Artigas A, Kesecioglu J, et al. The Eldicus prospective, observational study of triage decision making
in European intensive care units. Part II: intensive care benefit for the elderly. Crit Care Med 2012; 40: 132–138.
66 Andersen FH, Flaatten H, Klepstad P, et al. Long-term outcomes after ICU admission triage in octogenarians.
Crit Care Med 2017; 45: e363–e371.
67 Storms AD, Chen J, Jackson LA, et al. Rates and risk factors associated with hospitalization for pneumonia with
ICU admission among adults. BMC Pulm Med 2017; 17: 208.
68 Heyland D, Cook D, Bagshaw SM, et al. The very elderly admitted to ICU: a quality finish? Crit Care Med 2015;
43: 1352–1360.
69 Valley TS, Sjoding MW, Ryan AM, et al. Association of intensive care unit admission with mortality among
older patients with pneumonia. JAMA 2015; 314: 1272–1279.
70 Chen J-H, Chang S-S, Liu JJ, et al. Comparison of clinical characteristics and performance of pneumonia severity
score and CURB-65 among younger adults, elderly and very old subjects. Thorax 2010; 65: 971–977.
71 Sanz F, Morales-Suárez-Varela M, Fernández E, et al. A composite of functional status and pneumonia severity
index improves the prediction of pneumonia mortality in older patients. J Gen Intern Med 2018; 33: 437–444.
72 Charles PGP, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or
vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375–384.
73 Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic
Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis
2007; 44: Suppl. 2, S27–S72.
74 de Lange DW, Brinkman S, Flaatten H, et al. Cumulative prognostic score predicting mortality in patients older
than 80 years admitted to the ICU. J Am Geriatr Soc 2019; 67: 1263–1267.
75 Blanch L, Abillama FF, Amin P, et al. Triage decisions for ICU admission: report from the Task Force of the
World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care 2016; 36: 301–305.
76 Bassford C. Decisions regarding admission to the ICU and international initiatives to improve the
decision-making process. Crit Care 2017; 21: 174.
77 Capuzzo M, Volta C, Tassinati T, et al. Hospital mortality of adults admitted to intensive care units in hospitals
with and without intermediate care units: a multicentre European cohort study. Crit Care 2014; 18: 551.
78 Leblanc G, Boumendil A, Guidet B. Ten things to know about critically ill elderly patients. Intensive Care Med
2017; 43: 217–219.
79 Fung HB, Monteagudo-Chu MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother
2010; 8: 47–62.
80 Fernández-Sabé N, Carratalà J, Rosón B, et al. Community-acquired pneumonia in very elderly patients:
causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003; 82: 159–169.
81 Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant
community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014; 58: 5262–5268.
82 Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in
community-acquired pneumonia. Ann Am Thorac Soc 2015; 12: 153–160.
83 Han X, Zhou F, Li H, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on
mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infect Dis 2018; 18: 192.
84 Ferrer M, Travierso C, Cilloniz C, et al. Severe community-acquired pneumonia: characteristics and prognostic
factors in ventilated and non-ventilated patients. PLoS One 2018; 13: e0191721.
85 Villafuerte D, Aliberti S, Soni NJ, et al. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized
with community-acquired pneumonia. Respirology 2019; in press [https://doi.org/10.1111/resp.13663].
86 Simonetti AF, Viasus D, Garcia-Vidal C, et al. Management of community-acquired pneumonia in older adults.
Ther Adv Infect Dis 2014; 2: 3–16.
87 Viasus D, Núñez-Ramos JA, Viloria SA, et al. Pharmacotherapy for community-acquired pneumonia in the
elderly. Expert Opin Pharmacother 2017; 18: 957–964.
88 Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community-acquired
pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. 3, iii1–ii55.
89 File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the
efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob
Chemother 2011; 66: iii19–iii32.
90 Low DE, File TM, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the
efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob
Chemother 2011; 66: Suppl. 3, iii33–iii44.
91 Udeani G, Evans J, Cole P, et al. Ceftaroline fosamil for the treatment of community-acquired bacterial
pneumonia in elderly patients. Hosp Pract (1995) 2014; 42: 109–115.
92 Nicholson SC, Welte T, File TM, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with
ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia
requiring hospitalisation. Int J Antimicrob Agents 2012; 39: 240–246.
93 Amalakuhan B, Echevarria KL, Restrepo MI. Managing community-acquired pneumonia in the elderly - the next
generation of pharmacotherapy on the horizon. Expert Opin Pharmacother 2017; 18: 1039–1048.
https://doi.org/10.1183/16000617.0126-2019 14
COMMUNITY-ACQUIRED PNEUMONIA | C. CILLÓNIZ ET AL.
94 Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with
severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA
2015; 313: 677–686.
95 Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with
community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 2015; 163: 519–528.
96 Wan Y-D, Sun T-W, Liu Z-Q, et al. Efficacy and safety of corticosteroids for community-acquired pneumonia: a
systematic review and meta-analysis. Chest 2016; 149: 209–219.
97 Bi J, Yang J, Wang Y, et al. Efficacy and safety of adjunctive corticosteroids therapy for severe
community-acquired pneumonia in adults: an updated systematic review and meta-analysis. PLoS One 2016; 11:
e0165942.
98 Nasa P, Juneja D, Singh O, et al. Severe sepsis and its impact on outcome in elderly and very elderly patients
admitted in intensive care unit. J Intensive Care Med 2012; 27: 179–183.
99 Cillóniz C, Dominedò C, Magdaleno D, et al. Pure viral sepsis secondary to community-acquired pneumonia in
adults: risk and prognostic factors. J Infect Dis 2019; 220: 1166–1171.
100 Dong T, Cursio JF, Qadir S, et al. Discharge disposition as an independent predictor of readmission among
patients hospitalised for community-acquired pneumonia. Int J Clin Pract 2017; 71: e12935.
101 Neupane B, Walter SD, Krueger P, et al. Predictors of in-hospital mortality and re-hospitalization in older adults
with community-acquired pneumonia: a prospective cohort study. BMC Geriatr 2010; 10: 22.
102 Jain S, Khera R, Mortensen EM, et al. Readmissions of adults within three age groups following hospitalization
for pneumonia: Analysis from the Nationwide Readmissions Database. PLoS One 2018; 13: e0203375.
103 Bordon J, Wiemken T, Peyrani P, et al. Decrease in long-term survival for hospitalized patients with
community-acquired pneumonia. Chest 2010; 138: 279–283.
104 Girard TD, Self WH, Edwards KM, et al. Long-term cognitive impairment after hospitalization for
community-acquired pneumonia: a prospective cohort study. J Gen Intern Med 2018; 33: 929–935.
105 Eurich DT, Marrie TJ, Minhas-Sandhu JK, et al. Ten-year mortality after community-acquired pneumonia. A
prospective cohort. Am J Respir Crit Care Med 2015; 192: 597–604.
106 Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with
community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008; 87: 329–334.
107 Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and
sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165: 766–772.
108 Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on long-term mortality after pneumonia in
older people. J Am Geriatr Soc 2007; 55: 518–525.
109 Eurich DT, Marrie TJ, Minhas-Sandhu JK, et al. Risk of heart failure after community acquired pneumonia:
prospective controlled study with 10 years of follow-up. BMJ 2017; 356: j413.
110 Mortensen EM, Kapoor WN, Chang C-CH, et al. Assessment of mortality after long-term follow-up of patients
with community-acquired pneumonia. Clin Infect Dis 2003; 37: 1617–1624.
111 Sundin P-O, Udumyan R, Fall K, et al. Hospital admission with pneumonia and subsequent persistent risk of
chronic kidney disease: national cohort study. Clin Epidemiol 2018; 10: 971–979.
112 Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe pneumococcal pneumonia causes acute cardiac toxicity and
subsequent cardiac remodeling. Am J Respir Crit Care Med 2017; 196: 609–620.
113 Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and
subsequent risk of cardiovascular disease. JAMA 2015; 313: 264–274.
114 Corrales-Medina VF, Taljaard M, Yende S, et al. Intermediate and long-term risk of new-onset heart failure after
hospitalization for pneumonia in elderly adults. Am Heart J 2015; 170: 306–312.
115 Violi F, Cangemi R, Falcone M, et al. Cardiovascular complications and short-term mortality risk in
community-acquired pneumonia. Clin Infect Dis 2017; 64: 1486–1493.
116 Cangemi R, Calvieri C, Falcone M, et al. Relation of cardiac complications in the early phase of
community-acquired pneumonia to long-term mortality and cardiovascular events. Am J Cardiol 2015; 116:
647–651.
117 Restrepo MI, Reyes LF. Pneumonia as a cardiovascular disease. Respirology 2018; 23: 250–259.
118 Heyland DK, Garland A, Bagshaw SM, et al. Recovery after critical illness in patients aged 80 years or older: a
multi-center prospective observational cohort study. Intensive Care Med 2015; 41: 1911–1920.
119 Ferrante LE, Pisani MA, Murphy TE, et al. The association of frailty with post-ICU disability, nursing home
admission, and mortality: a longitudinal study. Chest 2018; 153: 1378–1386.
120 Becker S, Müller J, de Heer G, et al. Clinical characteristics and outcome of very elderly patients ⩾90 years in
intensive care: a retrospective observational study. Ann Intensive Care 2015; 5: 53.
121 Klapdor B, Ewig S, Pletz MW, et al. Community-acquired pneumonia in younger patients is an entity on its
own. Eur Respir J 2012; 39: 1156–1161.
122 Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired
pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International
cohort study results. Arch Intern Med 2009; 169: 1515–1524.
123 Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a
literature review. Thorax 2013; 68: 1057–1065.
https://doi.org/10.1183/16000617.0126-2019 15
COMMUNITY-ACQUIRED PNEUMONIA | C. CILLÓNIZ ET AL.
